Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J; German Hepatitis C-Registry. Stein K, et al. Among authors: naumann u. Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):76-83. doi: 10.1097/MEG.0000000000001923. Eur J Gastroenterol Hepatol. 2022. PMID: 32956186
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Berg T, et al. Among authors: naumann u. Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15. Aliment Pharmacol Ther. 2019. PMID: 30874328
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Cornberg M, Stoehr A, Naumann U, Teuber G, Klinker H, Lutz T, Möller H, Hidde D, Lohmann K, Simon KG. Cornberg M, et al. Among authors: naumann u. Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541. Viruses. 2022. PMID: 35891520 Free PMC article.
Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R).
Ohlendorf V, Schäfer A, Christensen S, Heyne R, Naumann U, Link R, Herold C, Schiffelholz W, Günther R, Cornberg M, Serfert Y, Maasoumy B, Wedemeyer H, Kraus MR. Ohlendorf V, et al. Among authors: naumann u. J Viral Hepat. 2021 Aug;28(8):1206-1218. doi: 10.1111/jvh.13546. Epub 2021 Jun 8. J Viral Hepat. 2021. PMID: 34003549
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group. Heidrich B, et al. Among authors: naumann u. PLoS One. 2014 Oct 10;9(10):e108751. doi: 10.1371/journal.pone.0108751. eCollection 2014. PLoS One. 2014. PMID: 25302676 Free PMC article.
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13. Gastroenterology. 2018. PMID: 29146520
261 results